Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923604 | 0.92 | KCNH2 (0.34) | SCN9AAAK1BRD4CREBBPSPR | |
| SCHEMBL29923492 | 0.89 | CPT2 (0.34) | SCN9ABRD4CREBBPKDM4CHTR2A | |
| SCHEMBL27214562 | 0.89 | CPT2 (0.34) | SCN9ABRD4CREBBPKDM4CHTR2A | |
| SCHEMBL29923339 | 0.88 | GPR119 (0.37) | SCN9AHSD17B10KDM4CSCN5A | |
| SCHEMBL29923145 | 0.88 | GPR119 (0.37) | SCN9AHSD17B10KDM4CSCN5A | |
| SCHEMBL29923128 | 0.88 | BRD4 (0.33) | AAK1BRD4CREBBPKDM4CHTR2C | |
| SCHEMBL29923626 | 0.88 | HTR2C (0.33) | SPRKDM4CP2RX7HTR2AHTR2C | |
| SCHEMBL29923610 | 0.88 | BRD4 (0.33) | AAK1BRD4CREBBPKDM4CHTR2C | |
| SCHEMBL29923313 | 0.87 | GPR119 (0.33) | SCN9ABRD4CREBBPSPRKDM4C | |
| SCHEMBL27214569 | 0.87 | KDM4C (0.38) | SCN9AHSD17B10KDM4CP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | TAAR1, HTR1A, HTR1F | SCN9A 1896/4885AAK1 1049/4885BRD4 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.